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SUMMARY
Development of hypoxic regions is an indicator of poor prognosis in many tumors. Here, we demonstrate that
HIF1a, the direct effector of hypoxia, partly through increases in SDF1a, induces recruitment of bone mar-
row-derived CD45+ myeloid cells containing Tie2+, VEGFR1+, CD11b+, and F4/80+ subpopulations, as
well as endothelial and pericyte progenitor cells to promote neovascularization in glioblastoma. MMP-9 ac-
tivity of bone marrow-derived CD45+ cells is essential and sufficient to initiate angiogenesis by increasing
VEGF bioavailability. In the absence of HIF1a, SDF1a levels decrease, and fewer BM-derived cells are re-
cruited to the tumors, decreasing MMP-9 and mobilization of VEGF. VEGF also directly regulates tumor
cell invasiveness. When VEGF activity is impaired, tumor cells invade deep into the brain in the perivascular
compartment.INTRODUCTION
When tumors encounter low oxygen tension, they adapt by pro-
moting expression of genes associated with anaerobic cell me-
tabolism, cell survival, angiogenesis, metastasis and invasion.
This transcriptional response pathway is mediated to a large ex-
tent by the dimeric transcription factor complexes of hypoxia-
inducible factor HIF1 and HIF2 (Giaccia et al., 2004; Lofstedt
et al., 2007). At normoxia, HIFa subunits are degraded, but
they are stabilized and activated under hypoxic conditions
and form complexes with the constitutively expressed tran-
scription factor ARNT/HIF1b (Giaccia et al., 2004; Lofstedt
et al., 2007).
Congruent with the observation that poor oxygenation, con-
comitant with HIF1a induction, is associated with a more aggres-
sive tumor phenotype, genetic ablation of HIF1a in various tu-
mors results in reduced tumor mass, increased apoptosis, and
retarded metastasis due in part to reduced vascular density
and inhibition of angiogenesis (Maxwell et al., 1997; Ryan
et al., 1998; Liao et al., 2007; Blouw et al., 2003). HIF1 activity
SIGNIFICANCE
HIF1a activity in tumors is associated with poor clinical outcome as indicated by their highly angiogenic, invasive, or met-
astatic nature. We found that HIF1a contributes to induction of SDF1a in tumor cells, which in turn promotes tumor progres-
sion by recruiting vascular modulatory bone marrow-derived cells to stimulate angiogenesis. These results provide the mo-
lecular mechanism by which HIF1a contributes to aggressive tumor progression and provides a rational basis for future
therapeutic modalities. The data also reveal a novel function for VEGF activity in directly affecting invasiveness of tumor
cells. VEGF prevents tumor cell migration along blood vessels but promotes tumor cell infiltration into the brain parenchyma.
Therefore, tumor cells use perivascular invasiveness as an evasive adaptation mechanism when angiogenesis is impaired.206 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsstimulates neovascularization by enabling tumor and host cells
to produce a variety of proangiogenic factors like VEGF-A,
VEGFR1, PDGF-B, FGF-2, and angiopoietins that stimulate
new blood vessel formation within hypoxic areas (Shweiki
et al., 1992) (Calvani et al., 2006; Holash et al., 1999; Okuyama
et al., 2006).
New blood vessel formation in tumors and ischemic tissues is
derived from the existing vasculature by activating proliferation
and migration of endothelial cells (angiogenesis) and recruiting
a heterogeneous population of bone-marrow-derived cells
(BMDCs), including endothelial progenitor cells (EPC), pericyte
progenitor cells (PPC), and CD45+ vascular modulatory cells
(Aghi and Chiocca, 2005; De Palma et al., 2005; Grunewald
et al., 2006; Heissig et al., 2002; Kopp et al., 2006; Lin et al.,
2006; Lyden et al., 2001; Pollard, 2004; Rafii et al., 2002; Rajantie
et al., 2004; Song et al., 2005). While EPCs incorporate into the
vasculature and differentiate into endothelial cells, PPCs envelop
blood vessels and mature into pericytes and vascular smooth
muscle cells.
CD45+ cells of monocytic lineage make up the largest and
most heterogeneous group of BMDCs that function as vascular
modulators, but are not physically part of the vasculature (Grune-
wald et al., 2006). Such cells include tumor-associated macro-
phages (TAMs) (Pollard, 2004) and immature monocytic cells
including Tie2+ monocytes (TEMs) (De Palma et al., 2005),
VEGFR1+ hemangiocytes (Hattori et al., 2002), and CD11b+
myeloid cells (Yang et al., 2004), all of which express the receptor
CXCR4 to some extent. Little is known about the factors that
enable the mobilization of BMDC from the bone marrow into
the blood stream and their recruitment and retention into the
tumor. The most prominent factors identified thus far include
VEGF, angiopoietin-1, PlGF and PDGF-B, which mobilize EPCs
and PPCs, respectively (Hattori et al., 2001; Li et al., 2006;
Rabbany et al., 2003; Gerhardt and Betsholtz, 2003), and
SDF1a, which can facilitate CXCR4+ BMDC retention within
tumors (Grunewald et al., 2006; Hattori et al., 2003). Supported
by recent data that ischemic tissues may recruit endothelial pro-
genitors and other CXCR4+ BMDCs, in part through increases in
HIF and its targets SDF1a and VEGF (Aghi et al., 2006; Ceradini
et al., 2004; De Falco et al., 2004; Petit et al., 2007), here we test
the hypothesis that hypoxic conditions in tumors as well as in
normal tissues promote neovascularization in a HIF-dependent
manner by mediating BMDC recruitment.
We assessed this hypothesis in an orthotopic mouse model of
glioblastoma (GBM, grade IV astrocytoma) because these ag-
gressive brain tumors are very hypoxic and highly angiogenic
(Zagzag et al., 2000), and loss of HIF1a activity in these tumors
blocks vascular remodeling and angiogenesis (Blouw et al.,
2003). We found that while tumor vessels in GBM are hyperdi-
lated, distorted, and leaky, tumor vessels in HIF-deficient
(HIFko) GBM remain slim and regularly shaped and are more re-
flective of normal brain vasculature. HIFko GBM, however,
adapt to their inability to form new vessels by co-opting and
moving along blood vessels, a phenomenon defined as perivas-
cular invasion, hence becoming more invasive (Blouw et al.,
2003). In the present study, we inquired about the mechanisms
by which HIF1a stimulates vascular remodeling and angiogene-
sis and blocks the perivascular invasive evasive adaptation
mechanism.RESULTS
HIF1 Recruits Bone Marrow-Derived Cells
to the Tumor Site
To test the hypothesis that GBMs promote BMDC-dependent
neovascularization in a HIF-dependent manner, we transplanted
bone marrow cells from b-actin-EGFP mice into lethally irradi-
ated Rag1-deficient (Ragko) mice. Four weeks later, mice were
implanted intracranially with HIF1a-proficient (WT-GBM) or
HIF1a-deficient (HIFko GBM) GBM cells. We found that GFP+
BMDCs were randomly distributed within the tumor and repre-
sented about 15%–20% of all cells in WT-GBM tumors, whereas
HIFko GBMs contained only about one-third this number
(Figure 1A). Normal brain recruited virtually no GFP+ cells. These
results indicate that HIF1a activity promotes recruitment of
a substantial number of BMDCs in GBM.
We next assessed the BMDC types recruited by HIF1 by fluo-
rescence-activated cell sorting (FACS) and immunohistochemi-
cal analyses of the tumor-derived GFP+ cell populations. WT-
GBM elicited about three times more CD45+ monocytic cells
and seven times more PDGFRb+/Sca-1+ PPCs than HIFko
GBM (Figure 1B). WT-GBM also contained nearly four times as
many EPCs as HIFko GBM (Figure 1B). Importantly, GFP+
BMDCs were comprised of about 8% EPCs and 2% PPCs, re-
spectively, while up to 90% (about 16% of total cells within the
tumor) were positive for the panleukocyte marker CD45
(Figure 1B). The majority of the CD45+ BMDCs were reminiscent
of CD11b+ monocytes/myeloid cells and F4/80+ macrophages,
with 5% comprised of Tie2+ expressing monocytes or
VEGFR1+ hemangiocytes (Figure 1C). All CD45+ subpopula-
tions were reduced 2- to 4-fold in HIFko GBM. These results in-
dicate that HIF1 activation results in recruitment of heteroge-
neous populations of BMDC. Given that all of these cell types
are diminished in HIFko GBM, our data suggest that a reduction
in the number of BMDCs may be the limiting factor in promoting
angiogenesis.
HIF1 Induces SDF1a in Tumor Cells
This result raises the question about the signaling events that re-
cruit BMDC in a HIF-dependent manner. Both VEGF, which is
implicated in the recruitment of vascular progenitor cells (Hattori
et al., 2001), and stromal-derived factor 1a (SDF1a/CXCL12),
which signals through CXCR4 and may retain CXCR4+ BMDC
in tumors (Grunewald et al., 2006; Hattori et al., 2003), are HIF1
target genes (Ceradini et al., 2004; Shweiki et al., 1992). Indeed,
WT-GBM produced about 4-fold higher levels of VEGF and
SDF1a than HIFko GBM (Figure 1D). While WT-GBM contained
clusters of SDF1a+ cells, HIFko GBM contained only few single
SDF1a+ cells within tumors (Figure 1E). Importantly, we found
that WT-GBM cells, but not HIFko GBM cells, upregulated
SDF1a mRNA under hypoxic conditions (Figure 1F), implying
that GBMs, through HIF1 and its target SDF1a, recruit
CXCR4+ BMDCs to the tumor site to facilitate new blood vessel
growth.
HIF1 Recruits MMP-9-Positive Monocytic
Cells from the Bone Marrow
If HIF1-induced BMDC influx regulates neovascularization, then
which of the BMDC are functionally significant in this processCancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc. 207
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsFigure 1. HIF1 Recruits Bone Marrow-Derived Cells to Orthotopic Glioblastomas
(A) Immunofluorescent analysis of GBM tumors. HIFko GBM contained4 times less GFP+ BMDCs (green) than WT-GBM (n = 4 to 5 fields per tumor of 7 tumors/
group). Angiogenic vasculature (red) in WT-GBMs was tortuous, hyperdilated, and distorted, whereas vessels in nonangiogenic HIFko GBMs appeared slim and
more regular. Scale bar, 50 mm.208 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsand how do they achieve angiogenic initiation in GBM? Clearly,
EPCs and PPCs could support new vessel formation by provid-
ing an additional source of endothelial cells and pericytes (Kopp
et al., 2006; Rajantie et al., 2004; Song et al., 2005). However, it
is less obvious what roles the heterogeneous CD45+ myeloid
cell populations play. Therefore, we used a candidate approach
to identify proangiogenic molecules produced or regulated by
vascular-modulating CD45+ BMDCs. Recent studies have
shown that these cells express matrix metalloproteinase
(MMP)-9 (Jodele et al., 2005; Page-McCaw et al., 2007; Yang
et al., 2004; Nozawa et al., 2006). We had discovered that
MMP-9, conveyed by inflammatory cells, enables an angiogenic
switch by making sequestered VEGF bioavailable for its recep-
tor VEGFR2 in pancreatic islet tumors (Bergers et al., 2000;
Nozawa et al., 2006). In human astrocytomas, MMP-9 ex-
pressed in inflammatory cells and the invading tumor cell com-
partment correlates with tumor progression (Hormigo et al.,
2006; Kunishio et al., 2003). We observed that the expression
of MMP-9 in GBM was substantially reduced in the absence of
HIF1 (Figure 2A). Similar to human GBMs, WT-GBM expressed
MMP-9 in monocytic cells including F4/80+ macrophages
and Tie2+, CD11b+, and VEGFR1+ myeloid populations
(Figure 2B). We also detected MMP-9 in a small subset of tumor
cells within the tumor mass and in single tumor cells infiltrating
the brain parenchyma, as visualized by double positivity for
SV40Tag and MMP-9, which were diminished in HIFko GBMs
(Figure 2C). Substrate-gel zymography revealed that most of
MMP-9 in the tumors was in an active form and reduced in HIFko
GBM (Figure 2D).
Given that HIFko GBM do not undergo vascular remodeling,
we hypothesized that the nonangiogenic behavior of HIFko
GBM is mainly caused by the substantial reduction of MMP-9-
expressing BMDCs in the tumors. The reduced levels of MMP-9
would then keep VEGF in a predominantly sequestered state.
Indeed, when we ectopically expressed active MMP-9 in
HIFko-GBM cells (HIFko MMP-9+) to increase intratumoral
MMP-9 levels (Figure 2E), tumors became hemorrhagic
(Figure 2F) and, to a certain extent, exhibited a tortuous, irregu-
larly shaped and hyperdilated vasculature indicative of vascular
remodeling (Figure 2G), keeping with the observation that an
early indication of VEGF activity is vascular hyperdilation
(Dvorak, 2000). Since the VEGF levels in HIFko GBM are about
3.5-fold less than in WT-GBM (Figure 1D), the magnitude of
these responses would be expected to be limited due to the
rather low VEGF levels. Thus, although VEGF is liberated from
the matrix in the presence of MMP-9, the total VEGF levels are
not sufficient to produce the vigorous angiogenesis seen in
WT-GBM. Indeed, we confirmed that the soluble VEGF fraction
was substantially higher in HIFko MMP-9+ GBM compared tomock transfectants (Figure 2H). Our data suggest that HIF1
regulates two steps of VEGF activity: it both induces VEGF levels
and regulates its mobilization from the ECM by recruiting mono-
cytes that transport MMP-9 to the tumor site.
MMP-9 Deficiency Impedes Vascular Remodeling
and Neovascularization in GBM
If MMP-9 is a critical downstream factor of HIF1a regulating an-
giogenesis, then MMP-9 deficiency should give rise to tumors
that, like HIFko GBMs, are nonangiogenic. We, therefore, gener-
ated MMP-9ko GBMs in the same manner we produced WT-
GBM and HIFko GBMs (Blouw et al., 2003). Both MMP-9ko
GBM and WT-GBM cells gave rise to similar numbers of soft
agar colonies (Figure S1). MMP-9ko GBMs injected into MMP-
9ko mice exhibited typical features of high-grade astrocyto-
mas/GBMs, and although they did not differ from WT-GBM in
proliferation, these mice exhibited modestly longer survival times
than wild-type mice bearing WT-GBM (Figure S1).
We found that the majority of tumor vessels from MMP-9ko tu-
mors were slim, elongated, and regularly shaped as visualized by
fluorescent angiography, similar to blood vessels in normal
brain, and in contrast to the distorted and angiogenic tumor
vasculature from WT-GBM (Figure 3A). Congruent with the mor-
phologic changes of an angiogenic tumor vasculature, we ob-
served VEGF-VEGFR2-complex formation, which marks the ac-
tivated, angiogenic state on endothelial cells (Bergers et al.,
2000; Brekken et al., 2000) (Figure 3C), and RGS-5 expression
(Figure 3D), a marker of activated pericytes (Berger et al.,
2005; Bondjers et al., 2003), in WT-GBMs but not in MMP-9ko
tumors (Figures 3C and 3D). These results indicate that tumor
vessels in the absence of MMP-9 did not undergo vascular
remodeling.
Notably, the inability of VEGF to bind to its receptor in MMP-
9ko tumors was not caused by a severe reduction in VEGF or
its receptor VEGFR2 (Figures 3B and 3E) because VEGF levels
were comparable to those of WT-GBM (Figure S2). However,
most of the VEGF-164, the predominant VEGF isoform in
GBM, was bound to the extracellular matrix and cell surface of
MMP-9ko tumor cells and, unlike WT-GBM, was not present in
the supernatant (Figures 3F and 3G). These data confirm our ob-
servation in HIFko MMP-9+ tumors that MMP-9 is an important
initiator of angiogenesis in GBM by releasing sequestered VEGF
and making it bioavailable to its receptor VEGFR2.
Bone Marrow-Derived MMP-9+ Cells Are Sufficient
to Initiate the Angiogenic Switch in GBM
To determine whether MMP-9 in tumor cells or host cells is
critical for the angiogenic phenotype, we implanted WT-GBM
cells into MMP-9ko mice (Figure 4A), and MMP-9ko GBMs into(B) Fluorescence-activated cell sorting (FACS) analysis of GBM tumors. HIF1 recruited three distinct GFP+ BMDC populations to the tumor site: CD45+ mono-
cytes, endothelial progenitors (EPC) (VE-Cadherin+/VEGFR2+), and pericyte progenitors (PPC) (Sca1+/PDGFRb+) (n = 4 to 5/group). Error bars indicate ± SEM.
(C) FACS and immunohistochemical analyses. Subsets of the GFP+ BMDC population of CD45+ monocytes were VEGFR1+, Tie2+, CD11b+ myeloid cells, and
F4/80+ macrophages (all labeled in red, white arrowheads). Scale bar, 50 mm. All CD45+ subpopulations were reduced 2- to 4-fold in HIFko GBM. (n = 3 to
4/group). Error bars indicate ± SEM.
(D) ELISA assay. Intratumoral VEGF and SDF1a was 4 times higher in WT-GBM than HIFko GBM (n = 3 to 4/group).
(E) Immunohistochemical analysis of SDF1a. WT-GBM contained clusters of SDF1a+ cells (green, encircled), whereas SDF1a expression in HIFko GBM was
limited to a few single cells (white arrows). Scale bar, 50 mm.
(F) Real-time PCR analysis. HIF1 induced SDF1a in GBM tumor cells. WT-GBM and HIFko GBM cells were cultured under normoxic (20% pO2) or hypoxic con-
ditions (1% pO2) for 12 hr and harvested, and transcription levels of SDF1a were determined. Error bars indicate ± SEM.
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsFigure 2. MMP-9 Is Expressed in Various Subpopulations of CD45+ BMDC and in Infiltrating Tumor Cells
(A) Immunohistochemical analysis. WT-GBMs contained about 3.5 times more MMP-9+ cells than HIFko GBMs (n = 4 fields per tumor of 5 tumors/group). Scale
bar, 50 mm. Error bars indicate ± SEM.210 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCswild-type (WT) hosts (Figure 4B). In both instances, tumor ves-
sels were irregularly shaped and tortuous indicative of vascular
remodeling and showed VEGF/VEGFR2 binding, albeit to a lesser
extent than WT-GBM in WT hosts, indicating that as long as
a critical threshold of MMP-9 exists in tumors, angiogenesis
can be initiated. In both instances, MMP-9+ cell numbers were
reduced by 50% when compared to the WT situation (Figure 4E).
Interestingly, when we injected MMP-9ko GBMs into WT mice
whose bone marrow was reconstituted with MMP-9ko bone
marrow, MMP-9+ cells in the tumors dropped significantly by
3- to 4-fold compared to WT-GBM, while blood vessels were
more elongated and slim and did not exhibit VEGF:VEGFR2
activation, mimicking the phenotype of MMP-9ko tumor blood
vessels in a MMP-9ko host (Figures 4C and 4E). Similarly,
when we reconstituted the bone marrow of MMP-9ko mice har-
boring MMP-9ko GBM with WT bone marrow, the number
Figure 3. MMP-9-Deficient GBM Do Not Undergo Vascular Remodeling and Neovascularization
(A) FITC-lectin perfusion of the tumor vasculature and anti-CD31 immunohistochemical analysis (green). In the complete absence of MMP-9, tumor vessels did
not undergo vascular remodeling but contained a regular, slim, and dense vascular network (yellow arrowheads). All scale bars, 50 mm.
(B) Immunohistochemical analysis. VEGFR2 expression on tumor endothelial cells was apparent in WT-GBM and MMP-9ko GBM (yellow arrows).
(C) Immunohistochemical analysis. Activated tumor vessels were detected with the Gv39M antibody that recognizes the VEGF:VEGFR2 complex (brown) in
WT-GBM, but not in MMP-9ko tumors.
(D) In situ RNA hybridization. RGS-5 (blue), a marker for activated pericytes, was expressed in pericytes of WT-GBM, but not in MMP-9ko GBM.
(E) VEGF western blot analysis of tumor cells. In WT-GBM, soluble VEGF was detected in the supernatant of GBM. In MMP-9ko GBM, VEGF-164 was predom-
inantly sequestered in the ECM and bound to cell surfaces. VEGFko GBM served as negative controls.
(F) Quantification of soluble VEGF levels determined by densitometry of VEGF western blots shown in (E). Soluble VEGF was significantly decreased in the
absence of MMP-9. Error bars indicate SEM.
(G) ELISA. Ratio of soluble VEGF (in supernatant) and sequestered VEGF (ECM and cells) was determined in WT-GBM and MMP-9ko GBM. Soluble, mobilized
VEGF was significantly reduced in MMP-9ko GBM. Error bars indicate SEM.(B) RT-PCR analyses of fractionated cell populations from the tumor and immunohistochemical analyses. MMP-9 was expressed in F4/80+ macrophages,
CD11b+ myeloid cells, VEGFR1+ hemangiocytes, and in Tie2+ monocytes. Scale bar, 50 mm.
(C) MMP-9 was expressed in a small subset of tumor cells at the invading edge of WT-GBM, but not in the perivascular invasive areas of HIFko GBMs. (MMP-9+
cells, red; SV40Tag+ tumor cells, blue; blood vessels, green). Scale bar, 50 mm.
(D) Gelatin zymography. WT-GBM tumors contained predominantly active MMP-9 and, to a much lesser extent, MMP-2. In HIFko GBM, MMP-9 activity was
reduced. As controls, recombinant pro-MMP-9 and -2 as well as active MMP-9 and -2 were loaded, and MMP-activity was obliterated in the presence of the
MMP-inhibitor EDTA.
(E) Gelatin zymography. HIFko MMP-9+ cells that ectopically express MMP-9 had substantially higher MMP-9 activity than mock-infected control.
(F) HIFko MMP-9+ GBM, but not HIFko Mock control tumors, were hemorrhagic by gross morphology.
(G) Blood vessels in HIFko Mock control tumors were slim and elongated, whereas vessels in HIFko MMP-9+ tumors were rather distorted and hyperdilated.
(H) ELISA assay. Soluble VEGF was measured in GBM in the supernatant. Sequestered (bound) VEGF was determined both in the ECM and in GBM cells. Error
bars indicate SEM.Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc. 211
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsof MMP-9+ cells increased while blood vessels became en-
larged and distorted, exhibiting typical features of vascular re-
modeling concomitant with VEGF binding to its receptor (Figures
4D and 4E).
These data support the notion that a specific MMP-9 thresh-
old is required for the angiogenic switch and that, indeed,
BMDCs expressing MMP-9 have a significant effect on GBM an-
giogenesis.
MMP-9 Enables Recruitment of EPC and PPC
to the GBM Vasculature
To elucidate how MMP-9+ BMDCs promote GBM angiogenesis,
we analyzed whether lack of MMP-9 in bone marrow cells im-
pacts recruitment of vascular progenitor cells and CD45+ mye-
loid vascular support cells. Transplant experiments with actin-
Figure 4. MMP-9+ BMDCs Contribute to the
Angiogenic Switch in GBM
Immunohistochemical analysis and FITC-lectin perfusion
of mice (A–D). The activated tumor vasculature was iden-
tified by the presence of VEGF:VEGFR2 complexes on en-
dothelial cells. Cohorts of 6–13 mice were used. White
bars, 50 mm. Black bars, 75 mm.
(A) WT-GBM cells in MMP-9ko mice. Vascular remodeling
of tumor vessels was indicated by their irregular shape and
the presence of a few activated tumor vessels (yellow
arrowheads).
(B) MMP-9ko GBM cells in wild-type mice. Vascular re-
modeling of tumor vessels was indicated by their irregular
shape and the presence of a few activated tumor vessels
(yellow arrowheads).
(C) Wild-type mice, reconstituted with MMP-9ko bone
marrow, were injected with MMP-9ko GBM cells. Tumor
vessels contained areas of elongated and slim vessels
mimicking the phenotype of MMP-9ko tumor vessels
and did not exhibit VEGF:VEGFR2 activation on tumor en-
dothelial cells.
(D) MMP-9ko mice, reconstituted with wild-type bone
marrow, were injected with MMP-9ko GBM cells. Tumor
vessels appeared torturous, hyperdilated, and irregularly
shaped, concomitant with VEGF:VEGFR2 activation on
tumor endothelial cells.
(E) The number of MMP-9+ cells correlated with the angio-
genic phenotype of the tumors described in (A)–(D). Error
bars indicate SEM.
GFP bone marrow cells revealed a 4-fold reduc-
tion of VEGFR2+ GFP+ EPC incorporated into
tumor vessels when compared to WT-GBM
(Figure 5A). Using two different pericyte markers
(desmin and a-smooth muscle actin [aSMA])
to detect pericytes (Figure 5B), we also ob-
served about 50% less pericyte coverage in
the absence of MMP-9. Upon transplantation
of MMP-9ko GBM-bearing MMP-9ko mice
with WT bone marrow, pericyte coverage in-
creased, approximating the WT situation
(Figure 5B). In contrast, when we reconstituted
bone marrow of WT tumor-bearing mice with
MMP-9ko bone marrow, we lowered pericyte
coverage, indicating that a subpopulation of
pericytes is recruited from the bone marrow in a MMP-9-depen-
dent manner (Figure 5B).
Recruitment of CD45+ Cells Is Independent
of MMP-9 but Dependent on SDF1a
We then asked whether MMP-9 is also required for recruitment
of the CD45+ population of BMDC in GBM. We observed similar
numbers of CD45+ cells in MMP-9ko GBM and WT-GBM tumors
(Figure 5C). By contrast, we observed an3-fold reduction in the
number of CD45+ and F4/80+ cells in HIFko GBMs when com-
pared to WT tumors (Figure 5C). Similarly, while WT-GBM and
MMP-9ko GBM expressed comparable levels of SDF1a, HIFko
GBM expressed severely reduced levels of SDF1a, reflective
of the differing CD45+ cell influx in the respective tumors
(Figure 5C). These data suggest that GBMs recruit CXCR4+212 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsBMDC to the tumor site through HIF1 and its target SDF1a to
facilitate new blood vessel growth.
To demonstrate the functional significance of SDF1a in neo-
vascularization, we treated WT-GBM bearing mice with the
CXCR4 inhibitor AMD3100 (Petit et al., 2007). AMD3100 sub-
stantially reduced the recruitment of CXCR4+/CD45+ BMDC
(Figure 5D), and tumor vessels appeared slimmer and ‘‘normal-
ized’’ as observed when angiogenesis is inhibited (Figure 5E).
BMD-CD45+ Cells Are Sufficient
to Initiate Neovascularization in GBM
Since AMD3100 also blocks CXCR4+ EPC, we sought to inves-
tigate whether the CXCR4+ monocytic population is functionally
significant and sufficient in promoting the angiogenic switch.
While both EPC and PPC populations were reduced in MMP-
9ko GBM, we found that MMP-9ko GBM and WT-GBM con-
tained similar numbers of CD45+ BMDC (Figure 5C), indicating
that recruitment of these monocytic cells is independent of
MMP-9 in the bone marrow. This suggested that MMP-9ko tu-
mors were nonangiogenic, despite the unaltered levels of mono-
cytic cells, because CD45+ cells lacked MMP-9 necessary to
initiate neovascularization, whereas HIFko tumors were nonan-
giogenic because they had reduced numbers of CD45+ cells
and, thus, insufficient MMP-9 to commence neovascularization.
To assess the functional significance of MMP-9+ CD45 cells in
this process, we isolated MMP-9-proficient GFP+ CD45+ cells
from bone marrow of WT mice and injected them intravenously
into MMP-9ko mice bearing MMP-9ko GBM (Figure 5F). We
used MMP-9ko GFP+ CD45+ cells as controls. We confirmed
by zymogram analysis that injections of MMP-9+ CD45+ cells
led to MMP-9 activity in the tumor, whereas injection of MMP-
9ko CD45+ cells did not (Figure 5G), and that tumors recruited
GFP+ CD45+ MMP-9-proficient or -deficient cells at similar
levels (Figure 5H). The tumors that attracted CD45+ MMP-9+
BMDC exhibited hyperdilated and more irregularly shaped ves-
sels, whereas GBM that attracted CD45+ MMP-9ko cells did
not alter their slim vascular anatomy (Figures 5I and 5J). Notably,
we often detected MMP-9+ cells encircling enlarged tumor ves-
sels (Figure 5J), suggesting that MMP-9 may preferentially facil-
itate local ‘‘activation’’ of sequestered VEGF. We further noticed
that VEGFR2 activation occurred in tumors undergoing vascular
remodeling, but not in tumors that received CD45+MMP-9ko
cells (Figure 5K). Taken together with the results in Figures 3
and 4, these data reveal that MMP-9 expressed and secreted
by a heterogeneous group of CD45+ cells from the bone marrow
is sufficient to initiate angiogenesis by making sequestered
VEGF bioavailable to its receptor VEGFR2.
VEGF Is a Direct and Negative Regulator
of Perivascular Tumor Invasion
In view of our previous observation that genetic ablation of HIF1a
or VEGF (Blouw et al., 2003), which blocks the ability of GBM to
initiate VEGF-dependent neovascularization, results in a more
invasive phenotype, we reevaluated the paradigm of angiogene-
sis as being key to tumor progression. It is important to note that
the induced invasive mode in the absence of these angiogenic
factors was distinct from the invasive mode in WT-GBM because
tumor cells predominantly moved along blood vessels in the
brain parenchyma (Blouw et al., 2003; present paper;Figure 6A white arrows). In contrast, WT-GBMs have a more in-
filtrative behavior in which tumor cells percolate as single cells
through the brain parenchyma (Figure 6A, yellow arrows). Inter-
estingly, we found that MMP-9 was expressed in a subset of
these infiltrating cells, while MMP-9 was not detected in HIFko
GBMs migrating along blood vessels (Figure 2C). These data
support the hypothesis that MMP-9 facilitates infiltration of tu-
mor cells directly but is not implicated in the perivascular inva-
sive mode. Because MMP-9ko GBMs do not undergo vascular
remodeling, we predicted that they would display a more peri-
vascular invasive phenotype. We observed that GBM in the com-
plete absence of MMP-9 grew more diffusively into the brain pa-
renchyma than WT-GBM (Figure 6A). Notably, while WT-GBMs
in a WT host and WT-GBMs in an MMP-9ko host both preferen-
tially infiltrated into the brain parenchyma, loss of MMP-9 in the
tumor cell compartment alone was sufficient to tip the balance to
a more perivascular invasive mode, which was even more exag-
gerated in the complete absence of MMP-9 and comparable to
the phenotype observed in HIFko GBM tumors (Figure 6B). No-
tably, regardless of whether HIF1a or MMP9 was completely ab-
lated, disabling angiogenesis resulted in a perivascular invasive
phenotype.
These results point to a specific adaptation mechanism for
GBM when deprived of key angiogenic factors that drive
VEGF-dependent neovascularization and suggest that the
mechanisms of tumor cell infiltration and perivascular tumor
cell invasion are very distinct. Since perivascular tumor invasion
is negatively correlated with angiogenesis, we then tested the
hypothesis that VEGF is the negative regulatory factor. Indeed,
by ectopically expressing VEGF-164, the major VEGF isoform
expressed in GBM, we were able to convert HIFko GBMs, which
are highly invasive and produce low levels of VEGF, into noninva-
sive tumors with smooth borders (Figure 6C).
How does VEGF-induced angiogenesis block perivascular in-
vasion? Based on several reports that tumor cells can express
VEGF receptors (Lesslie et al., 2006), we asked whether VEGF
has a direct effect on the invasive behavior of GBM. Both WT-
GBM and HIFko GBM cell lines expressed VEGFR1 and -2 re-
ceptors to varying extents, as well as the coreceptors neuropi-
lin-1 (NP-1) and neuropilin-2 (NP-2) (Figure 6D). We then tested
the ability of VEGF to affect invasive behavior of GBM cells di-
rectly in vitro in a Boyden chamber assay. Both WT-GBM and
HIFko GBM cells were highly invasive in response to HGF, a stim-
ulator of GBM invasion (Abounader and Laterra, 2005; Eckerich
et al., 2007), but surprisingly, VEGF reduced their invasive be-
havior significantly (Figure 6F). Similarly, HIFko GBM cells over-
expressing VEGF were less invasive than their parental counter-
parts (Figure 6E). VEGF alone did not stimulate or inhibit
invasiveness of GBM cells. In summary, these results reveal
that VEGF acts as a direct negative regulator of perivascular
GBM tumor cell invasion.
DISCUSSION
HIF1 Is a Key Regulator for BMDC
Recruitment in Tumors
In this study, we have demonstrated that HIF1, in part by inducing
SDF1a, is a major recruitment regulator of bone marrow-derived
EPC, PPC, and monocytic vascular modulatory cells to endorseCancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc. 213
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsFigure 5. CD45+ MMP-9+ BMDCs Are Sufficient to Initiate Angiogenesis in GBM
(A) Wild-type mice or MMP-9ko mice, reconstituted with bone marrow from actin-GFP wild-type or MMP-9ko mice, respectively, were injected with WT-GBM or
MMP-9ko GBM cells. MMP-9ko GBM revealed a 4- to 5-fold reduction of VEGFR2+ (red) GFP+ (green) EPCs. Cohorts of five mice per group were used.214 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.
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VEGF transcription in GBM, but also increases VEGF activity by
recruiting CD45+ BMDC that carry and secrete the metalloprotei-
nase MMP-9 to the tumor site, which in turn makes sequestered
VEGF bioavailable for its receptor VEGFR2 (Figure 7). We found
that MMP-9 was expressed in all the CD45+ monocytic cell types
that have been implicated in angiogenesis, including TEMs,
VEGFR1+ hemangiocytes, CD11b+ immature myeloid cells,
and TAMs. These data suggest that MMP-9 is a critical molecule
for the different CD45+ vascular modulating cells to promote an-
giogenesis. Our result that MMP-9 expressed by CD45+ cells is
necessary and sufficient to drive neovascularization supports
this conclusion. We noticed that most VEGFR1+ hemangiocytes
and TEMs express MMP-9, which may explain why inhibition of
these cells impairs neovascularization, although these cell types
constitute less than 10% of the CD45+ population (De Palma
et al., 2005; Jin et al., 2006; Rafii et al., 2002). Importantly, our
study indicates that tumors need to have a threshold of MMP-9
levels to initiate the angiogenic switch.
We further revealed that not only the recruitment of EPCs, but
also that of PPC into tumors, depended on HIF1 activity and was
regulated by MMP-9. PPCs are critical for supplying tumor ves-
sels with sufficient pericytes and for supporting vessel stability
and endothelial cell survival in tumors (Song et al., 2005).
In contrast to several other studies (Jin et al., 2006; Jodele et al.,
2005), we did not observe that MMP-9 impacted the recruitment
of CD45+ BMDCs, although HIF1 activity did. One explanation for
the different recruitment mechanisms may lie in distinct signaling
circuits that drive recruitment of the respective BMDCs. In our
study, HIF1-induced VEGF and SDF1a in tumor cells dictated
the influx of BMDCs. While VEGF is an important factor for the ac-
tivation of MMP-9 in the bone marrow and subsequent mobiliza-
tion of vascular progenitor cells (Hattori et al., 2001), SDF1a may
be crucial for retaining CD45+ populations within the tumor (Gru-
newald et al., 2006) (Petit et al., 2007). This may explain why tu-
mors growing in a completely MMP-9-deficient environment,
which has comparably high SDF1a levels, have reduced numbers
of EPCs and PPCs that are recruited in response to VEGF activity
but unaltered levels of CD45+ cells. HIFko tumors exhibited re-
duced levels of both SDF1aand VEGF and recruited fewer vascu-
lar progenitors and CD45+ modulatory cells. We conclude that,
while HIF1 induces vascular progenitors and monocytic vascular
modulatory cells, it is the monocytic population that is sufficient todrive neovascularization. While these studies were performed in
an immunocompromised system, it is noteworthy that BMDC in-
flux was found to be independent of the host’s immune compe-
tence status in another orthotopic glioma model (Joanna Philips
and Z.W., unpublished data).
VEGF Regulates Invasiveness of Tumor Cells
Increased bioavailability of VEGF due to influx of MMP-9 express-
ing CD45+ cells not only induced angiogenesis, but also regulated
tumor cell invasiveness. VEGF prevented tumor cell migration
along blood vessels, but appeared to promote tumor cell infiltra-
tion into the brain parenchyma. This action of VEGF as a brake on
perivascular GBM tumor cell migration is surprising and novel. We
observed enhanced invasiveness in the GBM model when VEGF-
dependent neovascularization was blocked by genetically delet-
ing the angiogenic regulators VEGF, HIF1a or MMP-9 (Blouw
et al., 2003 and present paper). Tumor cells dispersed deep into
the brain parenchyma by using blood vessels as a freeway system
for perivascular tumor invasion. This invasive mode is distinct
from single cells infiltrating into the brain parenchyma and sug-
gests differing mechanisms, also supported by the fact that peri-
vascular tumorcell invasion is independent of MMP-9 and MMP-2
(Du et al., 2008). In contrast, infiltrating tumor cells at the invading
edge of WT-GBM expressed MMP-9, suggestive of MMP-9 as
a direct regulator in tumor cell infiltration. Further support for
this hypothesis stems from in vitro studies showing that decreas-
ing MMP-9 in GBM cells reduced their invasive capacity (Hu et al.,
2007; Lakka et al., 2004). How is perivascular invasion regulated
by VEGF? Our observation that both MMP-9ko and HIFko GBM
are well vascularized with a rather normal and more functional
vasculature than the distorted and sparse tumor vasculature of
WT-GBMs suggests that it is unlikely that tumor cells move out
due to insufficient oxygen and nutrient intake (Blouw et al.,
2003). Alternatively, VEGF could directly signal through tumor
cells and thereby affect their migration behavior. Congruent with
the observation that a variety of tumors express VEGFR1 or -2
and their neuropilin coreceptors (Lesslie et al., 2006; Rao,
2003), we found that GBM cells express VEGFR1 and -2 and neu-
ropilin 1 and 2 and that addition of VEGF to tumor cells or the gen-
eration of tumor cells that ectopically express high levels of VEGF-
164 reduced the migration capacity of tumor cells. Whether
VEGFR1 and -2 or neuropilins play a prominent role in regulating
tumor cell migration remains to be determined.(B) Tumor sections of the groups described in Figures 4A–4D were analyzed for the presence of pericytes on tumor vessels as detected by desmin (red) and
a-SMA-staining (red) and quantified using the ratios of red-labeled pericytes to green-labeled tumor vessels (anti-CD31 staining).
(C) GFP+CD45+ cells were substantially reduced in HIFko GBM when compared to WT-GBM or MMP-9ko GBM. ELISA assay. SDF1a levels were assessed
in tumor lysates of WT-GBM, HIFko GBM, and MMP-9ko GBM. Intratumoral SDF1a levels were lower in HIFko GBM than WT-GBM or MMP-9ko GBM (n = 3
to 4 per group).
(D) WT-GBM mice were treated with the CXCR4 inhibitor AMD3100 or with vehicle control for 2 weeks. AMD3100-treated tumors exhibited a 2- to 3-fold decrease
in CXCR4+ CD45+ cells compared to controls.
(E) AMD3100-treated mice demonstrated slimmer and more normalized tumor vessels, while control mice were hyperdilated and tortuous. Scale bars, 50 mm.
(F) Experimental design for assessing functional significance of MMP-9 in CD45+ BMDCs in initiating tumor angiogenesis.
(G) Zymogram analysis of MMP-9ko GBMs from mice that either received GFP+MMP-9+ or GFP+MMP-9ko CD45+ cells. A spleen lysate from a wild-type animal
served as a positive control for MMP-9.
(H) Comparable numbers of i.v. injected MMP-9+ or MMP-9ko GFP+CD45+ cells were recruited to the tumor site. All scale bars, 50 mm.
(I) MMP-9ko GBMs that contained MMP-9+CD45+GFP+ cells (white arrowheads) exhibited irregularly shaped and hyperdilated vessels (yellow arrowheads)
whereas MMP-9ko GBMs that recruited MMP9koCD45+GFP+ cells (white arrowheads) did not.
(J) MMP-9+ cells (white arrowheads) were preferentially located around hyperdilated vessels (yellow arrowheads).
(K) The vasculature of tumors containing MMP-9+CD45+GFP+ cells became activated (indicated by the presence of VEGF:VEGFR2 complexes on endothelial
cells). MMP-9ko tumors that recruited MMP-9ko CD45+ cells did not show VEGF:VEGFR2 complex formations. All error bars indicate ± SEM.Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc. 215
Cancer Cell
HIF-1 Regulates Tumorigenesis by Recruiting BMDCs
2Figure 6. VEGF Directly Inhibits Perivascular Tumor Invasion
(A) Fluorescent detection of tumor cells (anti-SV40-Tag antibody; red) and the vasculature (FITC-lectin; green). WT-GBM cells infiltrated as single cells into the
brain parenchyma without associating with blood vessels (yellow arrows) or invaded alongside blood vessels (perivascular invasion) in the brain (white arrows).
MMP-9ko GBMs were predominantly perivascular invasive. Black bar, 1.4 mm. White bar, 50 mm.
(B) Infiltrative and perivascular invasive modes of GBMs in different tumor cell/host combinations were quantified by immunohistochemical analysis on tumor
sections as in Figure 6A. Infiltrative cells were counted as cells in the brain without vessel association, whereas perivascular invasiveness of tumor cells was
graded from 0–3, where 1 indicates minimal distant spread of tumor cells and 3 indicates substantial and marked distant spread. Error bars indicate ± SD.
(C) HIFko GBM were stably transduced with a retrovirus expressing VEGF-164. While HIFko GBMs were perivascular invasive (white arrows), HIFko GBMs over-
expressing VEGF exhibited a smooth tumor border (dotted line) and did not invade. Scale bars, 50 mm.
(D) RT-PCR analysis revealed that both WT-GBM and HIFko GBM express VEGFR1, 2 and neuropilin1, 2.
(E and F) Boyden Chamber invasion assay. (E) Ectopic expression of VEGF in HIFko GBM or (F) addition of recombinant VEGF to HIFko GBM cells reduced tumor
cell migration by about 50% in response to HGF. VEGF alone had no effect. Error bars indicate ± SEM.16 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.
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HIF-1 Regulates Tumorigenesis by Recruiting BMDCsFigure 7. HIF-1 Is a Critical Regulator of BMDC Recruitment in
Tumors
Hypoxia in tumors increases HIF1, which, partly by inducing VEGF and
SDF1a in tumor cells, recruits BMDC including EPC, PPC, and CD45+
monocytic vascular modulatory cells to endorse vascular remodeling
in glioblastomas. SDF1a serves as a retention factor of CXCR4+ vascu-
lar progenitor and monocytic BMDC in GBM. HIF1 not only induces
VEGF transcription in GBM, but also increases VEGF activity by recruit-
ing CD45+ BMDC that carry and secrete MMP-9 to the tumor site,
which in turn makes sequestered VEGF bioavailable for its receptor
VEGFR2.
MMP-9+ cells overexpressing MMP-9 were generated by retroviral trans-
duction of HIFko GBM cells with an autoactivating form of murine MMP-9
(kind gift from Dr. Elaine Raines) (Gough et al., 2006). HIFko Mock control
cells were generated with an empty retroviral construct. All animal hous-
ing, care, and experiments were performed in accordance with the UCSF
institutional and national guidelines and regulations governing care of labora-
tory mice.
Bone Marrow Transplantation
Bone marrow was harvested from 6- to 8-week-old b-actin-EGFP Rag1ko or
Rag1ko MMP-9ko/ko mice by flushing the femurs and tibias with 2% FBS in
phosphate-buffered saline (PBS). Cells (2 3 106) were intravenously (i.v.) in-
jected through the tail vein of lethally irradiated (10 Gy) recipient mice. Tumor
cell implantation was performed intracranially (i.c.) 4 weeks later.
Intracranial Implantation of Astrocytomas
Six- to eight-week-old FvBN Rag1ko or Rag1ko/MMP-9ko mice were im-
planted i.c. as described previously (Blouw et al., 2003) with 2.5 ml of 0.7 3
106 WT-GBM, HIFko, MMP-9ko, or HIFko MMP-9+ GBM cells. All mice
were sacrificed 14 to 21 days after tumor cell implantation. Tumors were iso-
lated from the brain and prepared for flow cytometric analyses, immunohisto-
chemical staining, or protein and RNA isolation as described below. All implan-
tation experiments were repeated up to three times for a total of up to ten mice
per group.
AMD3100 Treatment
Ten FvBN Rag1ko mice injected i.c. with WT-GBM cells were randomized into
two cohorts for AMD3100 treatment or control treatment. Beginning 3 days
prior to tumor cell implantation, AMD3100 (Sigma) or PBS was subcutaneously
(s.c.) administered at 1.25 mg/kg twice daily in the right and left flank for 2
weeks, with the exception of single doses on weekends. Experiments were
performed four times (n = 20 treated mice and 20 control mice).
Isolation of GFP+ CD45+ Bone Marrow Cells
CD45+ cells were isolated from the bone marrow of wild-type b-actin-EGFP
Ragko mice or MMP9 ko/ko b-actin-EGFP Ragko mice using a biotinylated
rat antibody against murine CD45 and the EasySep Biotin Selection Kit (Stem-
Cell Technologies). Isolated GFP+ CD45+ bone marrow cells (2 3 106) were
injected i.v. every 3 to 4 days for a total of four injections over 2 weeks into
MMP-9 ko/ko mice that had been implanted with MMP9ko GBM cells a day
prior to onset of CD45 cell injections. Experiments were repeated four times
with four to five mice per group.
Flow Cytometry
GBMs from GFP bone marrow-transplanted mice were prepared as single cell
suspensions as described (Song et al., 2005) and stained with the following an-
tibodies: FITC-, APC-, PE-, or biotin-conjugated rat antibodies against murine
CD45, Tie-2, F4/80, VEGFR2, and PDGFRb (eBioscience, San Diego, CA),
CXCR4 and Sca-1 (BD Biosciences), VEGFR1 clone MF1 (Imclone Systems,
New York, NY), and a goat antibody against murine VE-cadherin (Santa Cruz
Biotechnology, Santa Cruz, CA). CD45+ populations were analyzed for ex-
pression of Tie-2, F4/80, CD11b, and VEGFR1. EPCs were identified by dou-
ble-positivity for VEGFR2 and VE-cadherin. PPCs were detected by doubleClinical Implications
The observation that hypoxia is a driving force in BMDC-depen-
dent neovascularization of tumors also has clinical implications.
Hypoxia occurs not only in certain tumor types during progres-
sion, but also in tumors that undergo antiangiogenic therapy
due to vessel regression. Therefore, combinatorial treatment
modalities blocking both proangiogenic receptor tyrosine ki-
nase signaling circuits and the recruitment of vascular progeni-
tor and modulatory BMDCs may reveal synergistic effects and
survival benefit. Similarly, GBM patients undergo daily radiation
after surgery to kill as many remaining tumor cells as possible.
This treatment might be a double-edged sword because radia-
tion also mobilizes bone marrow cells into the blood stream
(Heissig et al., 2005) that could account for the fast tumor re-
lapse that often occurs in GBM patients. Our results suggest
that radiation should occur in combination with CXCR4 in-
hibitors or other BMDC-targeting agents to block BMDC recruit-
ment and subsequent neovascularization and regrowth of
tumors.
Our observation that tumor cells increase their perivascular in-
vasiveness in the absence of VEGF activity was also found in
a human GBM xenograft model treated with the VEGF inhibitor
SU5416 (Rubenstein et al., 2000). Moreover, a proinvasive adap-
tation has been inferred from MRI imaging in a subset of GBM
patients that had developed multifocal recurrence of tumors dur-
ing the course of anti-VEGF (bevacuzimab) therapy (M. Prados
and N. Butowski, personal communication). These data impli-
cate that GBMs impaired in angiogenesis, for example, when tar-
geted with anti-VEGF agents, can evade from their inability to in-
duce angiogenesis by becoming more invasive. It will, therefore,
be instrumental to identify pathways that simultaneously block
perivascular invasion and angiogenesis to improve current anti-
angiogenic therapeutic implications in GBM and potentially other
tumors.
EXPERIMENTAL PROCEDURES
Generation of WT-GBM, HIFko GBM, HIFko MMP-9+,
and MMP9ko GBM Transformed Mouse Astrocytes
Generation of WT-GBM and HIFko GBM transformed mouse astrocytes has
been described previously (Blouw et al., 2003). MMP-9ko GBM cells were gen-
erated from MMP-9ko/ko FvBN Ragko mice using the same approach. HIFkoCancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc. 217
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flow cytometer (Becton Dickinson, NJ) and analyzed using FlowJo software
(Tree Star Inc., Ashland, OR). Experiments were repeated up to five times,
with two to three independent tumor samples for each combination of markers
analyzed.
Tissue Preparation
To prepare tissues for immunohistochemical staining, mice were anesthetized
and cardiac-perfused with PBS and 4% paraformaldehyde (PFA) and embed-
ded into paraffin or OCT.
Immunohistochemistry
Frozen or paraffin sections were used for immunohistochemical analysis. To
visualize the vasculature, mice were intravenously injected with FITC- or Rho-
damine-conjugated lectin prior to PBS/PFA heart perfusion and fixation. Ves-
sel imaging on frozen sections was enhanced by staining sections with a 1:100
dilution of a rat anti-mouse CD31 antibody (BD Biosciences). BMDC popula-
tions were analyzed on frozen sections by staining with 1:500 dilutions of rat
anti-mouse CD45 and CD11b (BD Biosciences), 1:100 Tie-2 (eBioscience),
1:500 F4/80 (Serotec, Raleigh, NC), and 1:150 VEGFR1 clone MF1 (Imclone
Systems) antibodies. MMP-9 was detected with a 1:500 dilution of a rabbit
anti-MMP-9 antibody (Behrendtsen and Werb, 1997). Staining of SDF1a was
performed on frozen sections using a rabbit anti-SDF1a antibody (1:100,
Cell Sciences, Canton, MA). VEGFR2 staining was performed on paraffin-em-
bedded sections with a goat anti-mouse VEGFR2 antibody (1:50, R&D Sys-
tems). VEGF-VEGFR2 complex was visualized in frozen sections with a mouse
monoclonal antibody Gv39M (1:50, EastCoast Bio, North Berwick, ME). Peri-
cytes were identified with a mouse anti-human desmin (1:100, DAKO Corp.)
and mouse anti-human alpha smooth muscle actin (1:500, DAKO Corp.). For
fluorescent visualization of antibody reactions, secondary antibodies were la-
beled with the fluorochromes AlexaFluor488, AlexaFluor594, or AlexaFluor633
(1:200; Molecular Probes, Eugene, OR), while nuclei were detected with DAPI.
Photomicrographs were taken with a Zeiss Axiovert 2 microscope using Open-
lab 3 software (Improvision, Lexington, MA) or a Zeiss LSM 510 laser scanning
confocal microscope using Zeiss LSM Image Browser software.
Quantification of Pericyte Coverage
Fluorescent images of tumor sections were collected on a Zeiss Axioskop 2
with 203 Plan Neofluar lenses and a Zeiss Axiocam color CCD. Red, green,
and blue staining was quantitatively evaluated using ImageJ v1.34 software
(NIH). The total area of CD31, desmin, or aSMA staining was obtained. The
fraction of pericyte coverage was calculated as the ratio of the area of desmin
or a-SMA staining (red) to the area of CD31 staining (green). For desmin stain-
ing, 8 to 17 tumor sections per group were evaluated. For a-SMA staining, four
to nine tumor sections per group were evaluated.
Substrate Zymography
Tumors were trimmed out of the brain and homogenized (1:3 w/v) in RIPA lysis
buffer and analyzed by gelatin zymography as described previously (Bergers
et al., 2000). EDTA (20 mM) was added to the gelatinase buffer overnight to
confirm that the proteases were metalloproteinases.
RNA Isolation, RT-PCR, and Real-Time PCR Analysis
RNA isolation was performed on cell cultures or whole tissue with TRIzol Re-
agent (Invitrogen). First-strand cDNA was generated using the SuperScript II
First Strand Synthesis System (Invitrogen). Primer sequences are listed in
Figure S4.
Nonradioactive In Situ Hybridization
Nonradioactive in situ hybridization of RGS-5 was performed as published pre-
viously (Berger et al., 2005).
Extraction of VEGF and Immunoblotting
Supernatants of 70% confluent WT GBM and HIFko GBM cells were collected
for 20 hr in serum-free medium and Insulin-Transferrin-Selenium and concen-
trated 50-fold in a microconcentrator (Millipore). Cell extracts were prepared
by gently scraping off cells in 13 calcium and magnesium-free PBS followed
by extraction in RIPA buffer containing 13 protease inhibitors (Roche). ECM218 Cancer Cell 13, 206–220, March 2008 ª2008 Elsevier Inc.proteins were extracted after complete removal of cells from cell culture dishes
in RIPA buffer as described (Park et al., 1993). Western blot analysis was per-
formed with 15 mg protein for cell supernatants and 150 mg for ECM and cell
extracts and probed with a goat anti-mouse VEGF antibody (1:200; R&D Sys-
tems, Minneapolis, MN) or an anti-mouse tubulin antibody (1:5000; Calbio-
chem) as loading control. VEGF and tubulin was quantified by densitometry
using Image J 1.38.
SDF-1a and VEGF ELISA
SDF-1a or VEGF levels were determined by ELISA in WT GBM, HIFko GBM,
MMP-9ko GBM, and HIFko MMP9+ astrocytes or from dissected tumors or
blood of either WT GBM, MMP-9ko GBM, or HIFko GBM mice using the Quan-
tikine mouse SDF-1a kit and mouse VEGF kit (R&D Systems).
Invasion Assay
Fifty percent confluent HIFko or WT-GBM or HIFko-VEGF astrocytoma cells
were switched to serum-free DMEM medium containing no VEGF or VEGF
(50 ng/ml) for 18 hr, trypsinized, and seeded at 13 105 cells/well in 24-well ma-
trigel plates (Fluoroblock; BD Falcon) in medium containing 40ng/ml HGF with
either no VEGF or 100 ng/ml VEGF in the lower chamber. Invasion was as-
sayed after 20 hr using Calcein AM as substrate on a cytoflour (excitation
485/20; emission 530/35; 50% gain).
Statistical Analysis
All experiments were repeated two to four times. Statistical analyses were per-
formed with the Kruskal-Wallis H test or the two-tailed Student’s t test to de-
termine statistical significance, followed by a Mann-Whitney U test for pairwise
comparison. p values (exact significance) of <0.05 were considered statisti-
cally significant. Results are expressed as mean ± SEM or SD as indicated. Ka-
plan-Meier curves and the log-rank test were used to compare survival times
among the groups. All calculations were performed using SPSS v11.0 (SPSS
Inc., Chicago, IL).
SUPPLEMENTAL DATA
The Supplemental Data include four supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/3/
206/DC1/.
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